Search

Your search keyword '"Kuk, Deborah"' showing total 304 results
Start Over Author "Kuk, Deborah"
304 results on '"Kuk, Deborah"'

1. Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test

Author

Zauber, Ann G., Winawer, Sidney J., O’Brien, Michael J., Mills, Glenn M., Allen, John I., Feld, Andrew D., Jordan, Paul A., Fleisher, Martin, Orlow, Irene, Meester, Reinier G.S., Lansdorp-Vogelaar, Iris, Rutter, Carolyn M., Knudsen, Amy B., Mandelson, Margaret, Shaukat, Aasma, Mendelsohn, Robin B., Hahn, Anne I., Lobaugh, Stephanie M., Soto Palmer, Brittany, Serrano, Victoria, Kumar, Julie R., Fischer, Sara E., Chen, Jennifer C., Bayuga-Miller, Sharon, Kuk, Deborah, O’Connell, Kelli, and Church, Timothy R.

Published
2023
Full Text
View/download PDF

2. MicroRNA-203 predicts human survival after resection of colorectal liver metastasis

Author

Kingham, T Peter, Nguyen, Hoang CB, Zheng, Jian, Konstantinidis, Ioannis T, Sadot, Eran, Shia, Jinru, Kuk, Deborah, Zhang, Steven, Saltz, Leonard, D’Angelica, Michael I, Jarnagin, William R, Goodarzi, Hani, and Tavazoie, Sohail F

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Genetics, Biotechnology, Clinical Research, Cancer, Colo-Rectal Cancer, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Cohort Studies, Colorectal Neoplasms, Female, High-Throughput Nucleotide Sequencing, Humans, Liver Neoplasms, Male, MicroRNAs, Middle Aged, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, microRNA, miR-203, colorectal liver metastasis, survival, resection, Oncology and carcinogenesis
Abstract

BackgroundResection of colorectal liver metastasis (CRLM) can be curative. Predicting which patients may benefit from resection, however, remains challenging. Some microRNAs (miRNAs) become deregulated in cancers and contribute to cancer progression. We hypothesized that miRNA expression can serve as a prognostic marker of survival after CRLM resection.ResultsMiR-203 was significantly overexpressed in tumors of short-term survivors compared to long-term survivors. R1/R2 margin status and high clinical risk score (CRS) were also significantly associated with short-term survival (both p = 0.001). After adjusting for these variables, higher miR-203 expression remained an independent predictor of shorter survival (p = 0.010). In the serum cohort, high CRS and KRAS mutation were significantly associated with short-term survival (p = 0.005 and p = 0.026, respectively). After adjusting for CRS and KRAS status, short-term survivors were found to have significantly higher miR-203 levels (p = 0.016 and p = 0.033, respectively).Materials and methodsWe employed next-generation sequencing of small-RNAs to profile miRNAs in solid tumors obtained from 38 patients who underwent hepatectomy for CRLM. To validate, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed on 91 tumor samples and 46 preoperative serum samples.ConclusionsAfter CRLM resection, short-term survivors exhibited significantly higher miR-203 levels relative to long-term survivors. MiR-203 may serve as a prognostic biomarker and its prognostic capacity warrants further investigation.

Published
2017

3. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma

Author

Shoushtari, Alexander N, Munhoz, Rodrigo R, Kuk, Deborah, Ott, Patrick A, Johnson, Douglas B, Tsai, Katy K, Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J, Luke, Jason J, Gangadhar, Tara C, Salama, April KS, Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B, Algazi, Alain P, Ribas, Antoni, Wolchok, Jedd D, and Postow, Michael A

Subjects
Clinical Trials and Supportive Activities, Cancer, Clinical Research, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Female, Follow-Up Studies, Humans, Liver Neoplasms, Male, Melanoma, Middle Aged, Mucous Membrane, Neoplasm Staging, Nivolumab, Prognosis, Programmed Cell Death 1 Receptor, Retrospective Studies, Skin Neoplasms, Survival Rate, acral melanoma, anti-programmed cell death receptor 1, immunotherapy, mucosal melanoma, nivolumab, pembrolizumab, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundTherapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.MethodsA multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival and overall survival were assessed using the Kaplan-Meier method.ResultsSixty individuals were identified, including 25 (42%) with acral melanoma and 35 (58%) with mucosal melanoma. Fifty-one patients (85%) had received previous therapy, including 77% who had previously received ipilimumab. Forty patients (67%) received pembrolizumab at a dose of 2 mg/kg or 10 mg/kg, and 20 (33%) received nivolumab at a doses ranging from 0.3 to 10 mg/kg every 2 to 3 weeks. The objective response rate was 32% (95% confidence interval, 15%-54%) in patients with acral melanoma and 23% (95% confidence interval, 10%-40%) in those with mucosal melanoma. After a median follow-up of 20 months in the acral melanoma group and 10.6 months in the mucosal melanoma group, the median progression-free survival was 4.1 months and 3.9 months, respectively. Only 2 patients (3%) discontinued treatment because of toxicity.ConclusionsResponse rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354-3362. © 2016 American Cancer Society.

Published
2016

4. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy

Author

Chow, Oliver S, Kuk, Deborah, Keskin, Metin, Smith, J Joshua, Camacho, Niedzica, Pelossof, Raphael, Chen, Chin-Tung, Chen, Zhenbin, Avila, Karin, Weiser, Martin R, Berger, Michael F, Patil, Sujata, Bergsland, Emily, and Garcia-Aguilar, Julio

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Clinical Trials and Supportive Activities, Clinical Research, Biotechnology, Cancer, Genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Chemoradiotherapy, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Male, Middle Aged, Mutation, Neoadjuvant Therapy, Prognosis, Prospective Studies, Proto-Oncogene Proteins p21(ras), Rectal Neoplasms, Retrospective Studies, Survival Rate, Tumor Suppressor Protein p53, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThe response of rectal cancers to neoadjuvant chemoradiation (CRT) is variable, but tools to predict response remain lacking. We evaluated whether KRAS and TP53 mutations are associated with pathologic complete response (pCR) and lymph node metastasis after adjusting for neoadjuvant regimen.MethodsRetrospective analysis of 229 pretreatment biopsies from patients with stage II/III rectal cancer was performed. All patients received CRT. Patients received 0-8 cycles of FOLFOX either before or after CRT, but prior to surgical excision. A subset was analyzed to assess concordance between mutation calls by Sanger Sequencing and a next-generation assay.ResultsA total of 96 tumors (42 %) had KRAS mutation, 150 had TP53 mutation (66 %), and 59 (26 %) had both. Following neoadjuvant therapy, 59 patients (26 %) achieved pCR. Of 133 KRAS wild-type tumors, 45 (34 %) had pCR, compared with 14 of 96 (15 %) KRAS mutant tumors (p = .001). KRAS mutation remained independently associated with a lower pCR rate on multivariable analysis after adjusting for clinical stage, CRT-to-surgery interval and cycles of FOLFOX (OR 0.34; 95 % CI 0.17-0.66, p

Published
2016

5. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer

Author

Nixon, Iain J, Wang, Laura Y, Migliacci, Jocelyn C, Eskander, Antoine, Campbell, Michael J, Aniss, Ahmad, Morris, Lilah, Vaisman, Fernanda, Corbo, Rossana, Momesso, Denise, Vaisman, Mario, Carvalho, Andre, Learoyd, Diana, Leslie, William D, Nason, Richard W, Kuk, Deborah, Wreesmann, Volkert, Morris, Luc, Palmer, Frank L, Ganly, Ian, Patel, Snehal G, Singh, Bhuvanesh, Tuttle, R Michael, Shaha, Ashok R, Gönen, Mithat, Pathak, K Alok, Shen, Wen T, Sywak, Mark, Kowalski, Luis, Freeman, Jeremy, Perrier, Nancy, and Shah, Jatin P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Age Factors, Brazil, Cell Differentiation, Decision Support Techniques, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, New South Wales, North America, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies, Risk Assessment, Risk Factors, Thyroid Neoplasms, Treatment Outcome, Clinical Sciences, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundAge is a critical factor in outcome for patients with well-differentiated thyroid cancer. Currently, age 45 years is used as a cutoff in staging, although there is increasing evidence to suggest this may be too low. The aim of this study was to assess the potential for changing the cut point for the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system from 45 years to 55 years based on a combined international patient cohort supplied by individual institutions.MethodsA total of 9484 patients were included from 10 institutions. Tumor (T), nodes (N), and metastasis (M) data and age were provided for each patient. The group was stratified by AJCC/UICC stage using age 45 years and age 55 years as cutoffs. The Kaplan-Meier method was used to calculate outcomes for disease-specific survival (DSS). Concordance probability estimates (CPE) were calculated to compare the degree of concordance for each model.ResultsUsing age 45 years as a cutoff, 10-year DSS rates for stage I-IV were 99.7%, 97.3%, 96.6%, and 76.3%, respectively. Using age 55 years as a cutoff, 10-year DSS rates for stage I-IV were 99.5%, 94.7%, 94.1%, and 67.6%, respectively. The change resulted in 12% of patients being downstaged, and the downstaged group had a 10-year DSS of 97.6%. The change resulted in an increase in CPE from 0.90 to 0.92.ConclusionsA change in the cutoff age in the current AJCC/UICC staging system from 45 years to 55 years would lead to a downstaging of 12% of patients, and would improve the statistical validity of the model. Such a change would be clinically relevant for thousands of patients worldwide by preventing overstaging of patients with low-risk disease while providing a more realistic estimate of prognosis for those who remain high risk.

Published
2016

10. Supplementary Figure 2 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

11. Data from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 1 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legends from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 4 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Author

Kitano, Shigehisa, primary, Postow, Michael A., primary, Ziegler, Carly G.K., primary, Kuk, Deborah, primary, Panageas, Katherine S., primary, Cortez, Czrina, primary, Rasalan, Teresa, primary, Adamow, Mathew, primary, Yuan, Jianda, primary, Wong, Philip, primary, Altan-Bonnet, Gregoire, primary, Wolchok, Jedd D., primary, and Lesokhin, Alexander M., primary

Published
2023
Full Text
View/download PDF

18. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas

Author

Gounder, Mrinal, Desai, Ved, Kuk, Deborah, Agaram, Narasimhan, Arcila, Maria, Durham, Benjamin, Keohan, Mary L., Dickson, Mark A., D’Angelo, Sandra P., Shukla, Neerav, Moskowitz, Craig, Noy, Ariela, Maki, Robert G., Herrera, Diego Adrianzen, Sanchez, Armando, Krishnan, Anita, Pourmoussa, Andrew, Qin, Li-Xuan, and Tap, William D.

Published
2015
Full Text
View/download PDF

28. T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease

Author

Goldberg, Jenna D., Linker, Alex, Kuk, Deborah, Ratan, Ravin, Jurcic, Joseph, Barker, Juliet N., Castro-Malaspina, Hugo, Giralt, Sergio, Hsu, Katharine, Jakubowski, Ann A., Jenq, Robert, Koehne, Guenther, Papadopoulos, Esperanza B., van den Brink, Marcel R.M., Young, James W., Boulad, Farid, Kernan, Nancy A., O’Reilly, Richard J., Prockop, Susan E., Yahalom, Joachim, Heller, Glenn, and Perales, Miguel-Angel

Published
2013
Full Text
View/download PDF

29. Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study

Author

Mendelsohn, Robin B., Winawer, Sidney J., Jammula, Anjani, Mills, Glenn, Jordan, Paul, O’Brien, Michael J., Close, Georgia M., Dorfman, Michael, Church, Timothy R., Mandelson, Margaret T., Allen, John, Feld, Andrew, Kauff, Noah D., Morgan, Georgia A., Kumar, Julie M.R., Serrano, Victoria, Bayuga-Miller, Sharon, Fischer, Sara E., Kuk, Deborah, and Zauber, Ann G.

Published
2017
Full Text
View/download PDF

30. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma

Author

Allen, Peter J., Kuk, Deborah, Castillo, Carlos Fernandez-del, Basturk, Olca, Wolfgang, Christopher L., Cameron, John L., Lillemoe, Keith D., Ferrone, Cristina R., Morales-Oyarvide, Vicente, He, Jin, Weiss, Matthew J., Hruban, Ralph H., Gönen, Mithat, Klimstra, David S., and Mino-Kenudson, Mari

Published
2017
Full Text
View/download PDF

31. Integrated NY-ESO-1 antibody and CD8⁺ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Author

Yuan, Jianda, Adamow, Matthew, Ginsberg, Brian A., Rasalan, Teresa S., Ritter, Erika, Gallardo, Humilidad F., Xu, Yinyan, Pogoriler, Evelina, Terzulli, Stephanie L., Kuk, Deborah, Panageas, Katherine S., Ritter, Gerd, Sznol, Mario, Halaban, Ruth, Jungbluth, Achim A., Allison, James P., Old, Lloyd J., Wolchok, Jedd D., and Gnjatic, Sacha

Published
2011

42. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Author

Huang, Alexander C., Postow, Michael A., Orlowski, Robert J., Mick, Rosemarie, Bengsch, Bertram, Manne, Sasikanth, Xu, Wei, Harmon, Shannon, Giles, Josephine R., Wenz, Brandon, Adamow, Matthew, Kuk, Deborah, Panageas, Katherine S., Carrera, Cristina, Wong, Phillip, Quagliarello, Felix, Wubbenhorst, Bradley, DAndrea, Kurt, Pauken, Kristen E., Herati, Ramin S., Staupe, Ryan P., Schenkel, Jason M., McGettigan, Suzanne, Kothari, Shawn, George, Sangeeth M., Vonderheide, Robert H., Amaravadi, Ravi K., Karakousis, Giorgos C., Schuchter, Lynn M., Xu, Xiaowei, Nathanson, Katherine L., Wolchok, Jedd D., Gangadhar, Tara C., and Wherry, E. John

Subjects
Apoptosis -- Research, Cancer research, Tumors -- Physiological aspects, Melanoma -- Physiological aspects, T cells -- Physiological aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used as indicators of clinical response; however, blood-based profiling to understand the mechanisms of PD-1 blockade has not been widely explored. Here we use immune profiling of peripheral blood from patients with stage IV melanoma before and after treatment with the PD-1-targeting antibody pembrolizumab and identify pharmacodynamic changes in circulating exhausted-phenotype CD8 T cells (T[sub.ex] cells). Most of the patients demonstrated an immunological response to pembrolizumab. Clinical failure in many patients was not solely due to an inability to induce immune reinvigoration, but rather resulted from an imbalance between T-cell reinvigoration and tumour burden. The magnitude of reinvigoration of circulating T[sub.ex] cells determined in relation to pretreatment tumour burden correlated with clinical response. By focused profiling of a mechanistically relevant circulating T-cell subpopulation calibrated to pretreatment disease burden, we identify a clinically accessible potential on-treatment predictor of response to PD-1 blockade., Author(s): Alexander C. Huang (corresponding author) [1, 2, 3, 4]; Michael A. Postow [5, 6]; Robert J. Orlowski [1, 2, 3, 4]; Rosemarie Mick [3, 4, 7]; Bertram Bengsch [2, [...]

Published
2017
Full Text
View/download PDF

44. Additional file 1: of Validation of diagnosis codes to identify side of colon in an electronic health record registry

Author

Luhn, Patricia, Kuk, Deborah, Carrigan, Gillis, Nussbaum, Nathan, Sorg, Rachael, Rohrer, Rebecca, Tucker, Melisa, Arnieri, Brandon, Taylor, Michael, and Meropol, Neal

Abstract

Table S1. Distribution of side identified by ICD code or abstraction for patients with Stage IV disease at diagnosis. Table S2. Distribution of side identified by ICD code or abstraction for patients with Stage I-III disease at diagnosis. Table S3. Accuracy of ICD codes for patients with Stage IV disease at diagnosis. Table S4. Accuracy of ICD codes for patients with Stage I-III disease at diagnosis (DOCX 19 kb)

Published
2019
Full Text
View/download PDF

45. Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

Author

Khozin, Sean, primary, Miksad, Rebecca A., additional, Adami, Johan, additional, Boyd, Mariel, additional, Brown, Nicholas R., additional, Gossai, Anala, additional, Kaganman, Irene, additional, Kuk, Deborah, additional, Rockland, Jillian M., additional, Pazdur, Richard, additional, Torres, Aracelis Z., additional, Zhi, Jizu, additional, and Abernethy, Amy P., additional

Published
2019
Full Text
View/download PDF

46. Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

Author

Zhi, Jizu, primary, Khozin, Sean, additional, Kuk, Deborah, additional, Torres, Aracelis Z., additional, Sorg, Rachael, additional, Lee, Shannon E., additional, Miksad, Rebecca A., additional, Pazdur, Richard, additional, and Abernethy, Amy Pickar, additional

Published
2018
Full Text
View/download PDF

48. Actual Ten-Year Survivors after Resection of Hepatocellular Carcinoma

Author

Zheng, Jian, Kuk, Deborah, Gönen, Mithat, Balachandran, Vinod P., Kingham, T. Peter, Allen, Peter J., D’Angelica, Michael I., Jarnagin, William R., and DeMatteo, Ronald P.

Subjects
Adult, Male, Metabolic Syndrome, Carcinoma, Hepatocellular, Liver Neoplasms, Middle Aged, Fibrosis, Article, Respiratory Tract Neoplasms, Tumor Burden, Survival Rate, Microvessels, Hepatectomy, Humans, Female, Neoplasm Invasiveness, Survivors, alpha-Fetoproteins, Neoplasm Grading, Neoplasm Recurrence, Local, Aged, Retrospective Studies
Abstract

Resection of hepatocellular carcinoma (HCC) offers a chance of cure, but recurrence is common and survival is often limited. The clinical and pathological characteristics of long-term survivors have not been well studied.We retrospectively reviewed 212 patients who underwent partial hepatectomy for HCC with curative intent from 1992 to 2006. Fifty patients who survived beyond 10 years were compared with 109 patients who died of recurrence within 10 years.Multivariate analysis showed that tumors5 cm (odds ratio [OR] 2.3, p = 0.04), solitary tumors (OR 3.2, p = 0.01), and absence of vascular invasion (OR 2.3, p = 0.04) were independently associated with actual 10-year survival. However, more than 20% of long-term survivors also possessed established poor prognostic factors, including α-fetoprotein1000 ng/mL, unfavorable serum inflammatory indices, tumor size10 cm, microvascular invasion, poor tumor differentiation, cirrhosis, and metabolic syndrome. None of the 10-year survivors had an R1 resection. While 77% of the short-term survivors developed recurrence within 2 years, 42% of the 10-year survivors developed recurrence during their decade of follow-up, although most of the recurrences among 10-year survivors were intrahepatic and amenable to further treatment. Among patients who survived beyond 10 years, 42% remained alive without recurrence.In this largest Western series of actual 10-year survivors after HCC resection, almost one in four patients survived over a decade, even though nearly half of this subset had developed recurrence. While many well-known variables were associated with a poor outcome, only a positive microscopic margin precluded long-term survival.

Published
2016

49. Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma

Author

Shoushtari, Alexander N., Munhoz, Rodrigo R., Kuk, Deborah, Ott, Patrick A., Johnson, Douglas B., Tsai, Katy K., Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J., Luke, Jason J., Gangadhar, Tara C., Salama, April K. S., Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B., Algazi, Alain, Ribas, Antoni, Wolchok, Jedd D., and Postow, Michael A.

Subjects
Article
Published
2016

Catalog

Books, media, physical & digital resources
See catalog results